Indications
Rezolsta is indicated, in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults and paediatric patients (aged 6years and older, weighing at least 25 kg).Genotypic testing should guide the use of Rezolsta.
Composition
- Active substance
- darunavir, cobicistat
- International name (INN)
- darunavir;cobicistat
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rezolsta
- Active substance
- darunavir, cobicistat
- ATC code
- J05AR14
- Therapeutic area
- HIV Infections